​

Novo Nordisk (NVO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NVO Stock Forecast

Novo Nordisk (NVO) stock forecast, based on 35 Wall Street analysts, predicts a 12-month average price target of $158.00, with a high of $160.00 and a low of $156.00. This represents a 172.04% increase from the last price of $58.08.

$50 $80 $110 $140 $170 $200 High: $160 Avg: $158 Low: $156 Last Closed Price: $58.08

NVO Stock Rating

Novo Nordisk stock's rating consensus is Buy, based on 35 Wall Street analysts. The breakdown includes 1 Strong Buy (2.86%), 26 Buy (74.29%), 7 Hold (20.00%), 1 Sell (2.86%), and 0 Strong Sell (0.00%).

Buy
Total 35 1 7 26 1 Strong Sell Sell Hold Buy Strong Buy

NVO Price Target Upside V Benchmarks

TypeNameUpside
StockNovo Nordisk172.04%
SectorHealthcare Stocks 35.94%
IndustryDrug Manufacturers - General Stocks37.39%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$158.40
Last Closing Price$58.08$58.08$58.08
Upside/Downside--172.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 253431-11
Mar, 252441-11
Feb, 252431-10
Jan, 252531112
Dec, 242521111
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 17, 2024Evan SeigermanBMO Capital$156.00$118.5831.56%168.60%
Sep 11, 2024Louise ChenCantor Fitzgerald$160.00$135.2318.32%175.48%
Aug 08, 2024Evan David SeigermanBMO Capital$160.00$126.1726.81%175.48%
Jun 10, 2024Jasper HellwegArgus Research$160.00$142.8811.98%175.48%
May 30, 2024James QuigleyGoldman Sachs$156.00$132.6817.58%168.60%
Apr 12, 2024Evan David SeigermanBMO Capital$163.00$125.4029.98%180.65%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 15, 2025Exane BNP ParibasUnderperforminitialise
Jan 10, 2025Deutsche BankBuyBuyhold
Jan 06, 2025BernsteinMarket Performupgrade
Dec 20, 2024JefferiesUnderperformUnderperformhold
Nov 22, 2024BMO CapitalOutperformOutperformhold
Oct 17, 2024BMO CapitalOutperformOutperformhold
Oct 10, 2024Cantor FitzgeraldOutperformOutperformhold
Sep 20, 2024Cowen & Co.BuyBuyhold
Sep 20, 2024BMO CapitalMixedMixedhold
Sep 11, 2024Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$5 $14 $23 $32 $41 $50 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.05$20.79$24.51$18.67-----
Avg Forecast$8.84$10.30$12.16$18.11$22.71$27.91$33.73$37.72$42.84
High Forecast$9.17$10.69$12.71$18.31$23.50$29.89$35.87$40.11$45.55
Low Forecast$8.45$9.85$11.25$17.77$21.91$25.33$33.58$37.56$42.66
Surprise %104.19%101.84%101.56%3.09%-----

Revenue Forecast

$100B $190B $280B $370B $460B $550B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$126.95B$140.80B$176.95B$232.26B-----
Avg Forecast$125.10B$139.79B$175.68B$226.80B$287.17B$350.19B$407.94B$443.79B$496.87B
High Forecast$128.69B$143.80B$181.72B$229.04B$292.28B$359.69B$427.83B$465.43B$521.10B
Low Forecast$120.85B$135.04B$165.59B$225.24B$282.07B$340.69B$406.60B$442.34B$495.24B
Surprise %1.47%0.72%0.72%2.41%-----

Net Income Forecast

$0 $90B $180B $270B $360B $450B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$42.14B$47.76B$55.52B$83.68B-----
Avg Forecast$252.30B$292.37B$343.87B$370.75B$102.06B$125.43B$151.60B$169.56B$192.55B
High Forecast$302.76B$350.84B$412.64B$444.90B$105.63B$134.36B$161.21B$180.31B$204.76B
Low Forecast$201.84B$233.89B$275.09B$296.60B$98.50B$113.84B$150.96B$168.84B$191.73B
Surprise %-83.30%-83.67%-83.85%-77.43%-----

NVO Forecast FAQ

Is Novo Nordisk stock a buy?

Novo Nordisk stock has a consensus rating of Buy, based on 35 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 26 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Novo Nordisk is a favorable investment for most analysts.

What is Novo Nordisk's price target?

Novo Nordisk's price target, set by 35 Wall Street analysts, averages $158 over the next 12 months. The price target range spans from $156 at the low end to $160 at the high end, suggesting a potential 172.04% change from the previous closing price of $58.08.

How does Novo Nordisk stock forecast compare to its benchmarks?

Novo Nordisk's stock forecast shows a 172.04% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the drug manufacturers - general stocks industry (37.39%).

What is the breakdown of analyst ratings for Novo Nordisk over the past three months?

  • April 2025: 27.27% Strong Buy, 36.36% Buy, 27.27% Hold, 9.09% Sell, 0% Strong Sell.
  • March 2025: 18.18% Strong Buy, 36.36% Buy, 36.36% Hold, 9.09% Sell, 0% Strong Sell.
  • February 2025: 20.00% Strong Buy, 40.00% Buy, 30.00% Hold, 10.00% Sell, 0% Strong Sell.

What is Novo Nordisk’s EPS forecast?

Novo Nordisk's average annual EPS forecast for its fiscal year ending in December 2024 is $22.71, marking a 21.64% increase from the reported $18.67 in 2023. Estimates for the following years are $27.91 in 2025, $33.73 in 2026, $37.72 in 2027, and $42.84 in 2028.

What is Novo Nordisk’s revenue forecast?

Novo Nordisk's average annual revenue forecast for its fiscal year ending in December 2024 is $287.17B, reflecting a 23.64% increase from the reported $232.26B in 2023. The forecast for 2025 is $350.19B, followed by $407.94B for 2026, $443.79B for 2027, and $496.87B for 2028.

What is Novo Nordisk’s net income forecast?

Novo Nordisk's net income forecast for the fiscal year ending in December 2024 stands at $102.06B, representing an 21.96% increase from the reported $83.68B in 2023. Projections indicate $125.43B in 2025, $151.6B in 2026, $169.56B in 2027, and $192.55B in 2028.